Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study intends to explore the predictive biomarkers by Next-generation sequencing (NGS)
and multiple immunohistochemistry (mIHC) for the treatment of SHR1210 in combination with
paclitaxel and platinum in advanced esophageal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sixth Affiliated Hospital, Sun Yat-sen University
Collaborators:
Jiangsu HengRui Medicine Co., Ltd. Nanjing Geneseeq Technology Inc